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Abstract: Rdc2 is a flavin-dependent halogenase from Pochonia chlamydosporia. Through the
introduction of a His6-tag to both the N- and C-termini, the isolation yield of Rdc2 from
Escherichia coli using Ni-NTA affinity chromatography was increased by three-fold. In vitro
reaction of Rdc2 and a flavin reductase (Fre) with seven different hydroxyquinolines revealed that
3-hydroxyquinoline (3), 5-hydroxyquinoline (5), 6-hydroxyquinoline (6) and 7-hydroxyquinoline
(7) can be specifically halogenated. These products were prepared by incubating the corresponding
substrates with IPTG-induced E. coli BL21(DE3)/Rdc2. They were respectively characterized as
3-hydroxy-4-chloroquinoline
(3a),
5-hydroxy-6-chloroquinoline
(5a),
5-chloro-6hydroxyquinoline (6a), and 7-hydroxy-8-chloroquinoline (7a) by NMR and MS analyses. This
work represents the first enzymatic preparation of chlorohydroxyquinolines and provides a “green”
method to synthesize this group of medicinally important compounds.
Keywords: Chlorination; Hydroxyquinolines; Halogenase; Substrate specificity;
Chlorohydroxyquinolines
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Introduction
Quinolines are common building blocks of numerous bioactive molecules, such as camptothecin
(anticancer),1 chloroquine (antimalarial),2 quinine (antimalarial),3 quinidine (antiarrhythmic),4 and
montelukast (anti-asthma) shown in Figure 1.5 Hydroxyquinolines are used as versatile chelating
agents and precursors to many pharmaceuticals and pesticides.6 For example, the derivatives of 8hydroxyquinoline can be used as multi-target compounds for the treatment of Alzheimer's disease.7
Hydroxyquinolines can be chemically synthesized from quinoline (1, Figure 2).
Halogenated compounds represent about
20% of pharmaceuticals on the market and
a quarter of those in the development
pipeline. Chlorohydroxyquinolines are
known to possess important medicinal
properties.8 For example, it has been
reported that 5-chloro-8-hydroxyquinoline
has significant antimycoplasma activity.9
However, preparation of halogenated
molecules relies on chemical methods.
Chemical halogenation typically requires
harsh reaction conditions including high
temperatures and toxic reagents (such as Figure 1. Quinoline-containing bioactive molecules. The
chlorine gas, hydrochloric acid, and quinoline moiety is shaded.
hydrogen peroxide). This is often
accompanied by poor selectivity, which results in unspecific halogenation and undesired
byproducts, creating difficulties in the purification process.10 For example, a previous research
showed that chlorination of quinoline at 160-190 C yielded a mixture of five chlorinated products,
including 3,4-dichloroquinoline, 3,4,6-trichloroquinoline, 3,4,8-trichloroquinoline, 3,4,6,8tetrachloroquinoline, and 3,4,6,7,8-pentachloroquinoline.11
Biological halogenation is considered as a better approach for its high selectivity. Flavindependent halogenases are a major player in the introduction of halogen in the biosynthesis of
halogenated natural products such as radicicol.12 Most reported flavin-dependent halogenases are
prokaryotic tryptophan halogenases. The
use of these enzymes in the preparation of
halogenated molecules was limited due to
their strict substrate specificity. A recent
work reported that a tryptophan 6halogenase (Th-Fal) from a thermophilic
halotolerant Streptomyces violaceusniger
can
halogenate
several
tryptophan
derivatives and aromatic substrates,
including
methyltryptophan,
5hydroxytryptophan, kynurenine, anthranilic
acid, and anthranilamide.13 However, there
is still a lack of a highly flexible halogenase
that can be used for a broad range of Figure 2. Structures of quinoline (1) and
hydroxyquinolines (2-8).
substrates. Rdc2 is the first flavin-

dependent halogenase identified from fungi. This enzyme is involved in the biosynthesis of
radicicol, specifically chlorinating monocillins (a group of resorcylic acids) at C-6. Rdc2 was
found to have flexible substrate specificity
and can work on similar macrolactones and
2
other structurally different compounds such
as oxytetracycline and curcumin.14 A
a
homology model of Rdc2 was built, which
indicates that the space at the active site of
b
this enzyme is large enough to accommodate
different
substrates.
Two
3
c
hydroxyisoquinolines were converted by
Rdc2 to two new halogenated derivatives.15
3a
d
However, specific enzymatic preparation of
chlorohydroxyquinolines has not been
4
e
previously reported. In this work, we
f
systematically tested the halogenation
capability using seven monohydroxylated
5
g
quinolines (2-8, Figure 2), including 2hydroxyquinoline (2), 3-hydroxyquinoline
(3),
4-hydroxyquinoline
(4),
55a
h
hydroxyquinoline (5), 6-hydroxyquinoline
(6), 7-hydroxyquinoline (7), and 86
i
hydroxyquinoline (8).
Results and discussion

j

6a

The reaction of Rdc2 requires a partner
enzyme, flavin reductase (Fre), which
7
k
reduces FAD to yield FADH2. We previously
constructed pZJ54 (pET28a-rdc2) and pZJ62
7a
l
(pET28a-fre) to purify N-His6-tagged
enzymes for in vitro reactions.14 In order to
8
m
get a higher Rdc2 yield, we designed a
construct with a His6-tag at both N- and Cn
terminal ends. To this end, the intron-free
rdc2 gene was amplified from the previously
constructed pZJ54 by PCR with Phusion
5
10
15
20
25 min
High-Fidelity DNA Polymerase (New
England Biolabs) using a pair of specific Figure 3. HPLC analysis (at 250 nm) of the in vitro
primers,
5'- reactions of Rdc2 with hydroxyquinolines (at 30C for 2
aaCATATGTCGGTACCCAAGTCTTG-3'
h) in the presence of Fre, NADH, FAD, O2 and NaCl. (a)
(the NdeI site is underlined) and 5'- Inactivated Rdc2 + 2; (b) Rdc2 + 2; (c) Inactivated Rdc2
+ 3; (d) Rdc2 + 3; (e) Inactivated Rdc2 + 4; (f) Rdc2 + 4;
aaAAGCTTAACTTTGTTGAGGCCAA-3'
(the HindIII site is underlined). The amplified (g) Inactivated Rdc2 + 5; (h) Rdc2 + 5; (i) Inactivated
gene was ligated into the cloning vector Rdc2 + 6; (j) Rdc2 + 6; (k) Inactivated Rdc2 + 7; (l) Rdc2
+ 7; (m) Inactivated Rdc2 + 8; (n) Rdc2 + 8.
pJET1.2 to yield pFC55. The Rdc2 gene was
then excised from pFC55 with NdeI and
HindIII and ligated into pET28a between the same sites to generate pFC56.

The plasmid pFC56 was introduced into
E. coli BL21(DE3) for protein expression.
The resulting strain was grown at 37 °C in
Luria-Bertani (LB) medium supplemented
with 50 µg mL-1 kanamycin. Protein
expression was induced at OD600 0.4-0.6
with 200 µM isopropyl-1-thio-β-Dgalactopyranoside (IPTG). The double His6tagged Rdc2 was purified by Ni-NTA
column at a yield of 18.5 mg L-1, which
represents a three-fold increase compared to
the N-terminal His6-tagged Rdc2.14 The
plasmid pZJ62 was introduced into E. coli
BL21-CodonPlus (DE3)-RIL for the
purification of Fre, as previously reported.14
Both enzymes were stored in 50% glycerol
at -20 C.

Figure 4. Selected 1H–1H COSY and HMBC correlations
of 3a, 5a, 6a and 7a.

We then conducted in vitro enzymatic assays with Rdc2, Fre, NADH, FAD, NaCl, O2 and seven
different hydroxyquinolines 2-8 as substrates. The reactions were incubated at 30 C for 2 h and
the negative controls were maintained under the same conditions with inactivated Rdc2. As shown
in Figure 3, HPLC analysis revealed that 3, 5, 6 and 7 can be converted to less polar products 3a,
5a, 6a and 7a by Rdc2, respectively. By contrast, no products were synthesized from 2, 4 and 8.
A comparison of the UV spectra of 3a, 5a, 6a and 7a with the corresponding substrates showed a
bathochromic shift (Figure S1), indicating that these products are chlorinated derivatives of 3, 5,
6 and 7. ESI-MS of all these products showed the [M+H]+ quasimolecular peaks at m/z 182 and
180, with a ratio of 3:1 (Figure S2), representing a characteristic isotope pattern of
monochlorinated compounds. All the hydroxyquinolines are isomers with a molecular weight of
145, while the molecular weight of 3a, 5a, 6a and 7a is 179, which is 34 mass units larger than the
substrates, indicating that they are indeed the chlorinated products.
To obtain sufficient amounts of chlorinated prod ucts for NMR spectroscopic analysis, we used
a whole-cell biotransformation approach. A total of 15 mg of 3, 5, 6 and 7 were separately fed into
Table 1. 1H (500 MHz) NMR data for 3a, 5a, 6a and 7a (CD3OD, δ in ppm, J in Hz).
Position

3a

5a

6a

7a

2

8.62 (1H, s)

8.83 (1H, d, J = 3.0)

8.80 (1H, d, J = 4.4)

8.84 (1H, d, J = 4.2)

3

-

7.56 (1H, dd, J = 8.5, 4.0)

7.59 (1H, dd, J = 8.4, 4.1)

7.44 (1H, dd, J = 8.1, 4.4)

4

-

8.72 (1H, d, J = 8.5)

8.49 (1H, d, J = 8.4)

8.31 (1H, d, J = 8.1)

5

8.17 (1H, d, J = 7.9)

-

-

7.79 (1H, d, J = 8.9)

6

7.63-7.70 (1H, overlap)

-

-

7.34 (1H, d, J = 8.9)

7

7.63-7.70 (1H, overlap)

7.55 (1H, d, 9.0)

7.58 (1H, d, J = 9.0)

-

8

7.99 (1H, d, J = 7.9)

7.68 (1H, d, 9.0)

7.94 (1H, d, J = 9.0)

-

500 mL of IPTG-induced fermentation broth of E. coli BL21(DE3)/pFC56, from which 4 mg of
3a, 3.2 mg of 5a, 4.5 mg of 6a and 4.3 mg of 7a were isolated in pure form, respectively.
The purified products were dissolved in methanol-d4 and the NMR spectra were acquired on a
Bruker AvanceIII HD Ascend-500 NMR instrument. To determine the chlorination position for
each product, 1H (Figures S3-S6), DEPTQ-135 (Figures S7-S10), HSQC, HMBC and 1H-1H
COSY spectra were recorded. The proton and carbon signals were assigned and are listed in Tables
1 and 2.
The 1H NMR spectrum of 3a showed five proton signals, including two doublet proton signals
( 7.99 and 8.17), an overlapped signal (2H,  7.63-7.70), and a singlet ( 8.62). This is one proton
less than the substrate, indicating that one of the CH of 3-hydroxyquinoline was chlorinated. The
1
H-1H COSY spectra showed a spin system that consists of the two doublet signals and two
overlapped proton signals, which suggested that the halogenation did not occurred on the benzene
ring and thus one of the protons on the pyridine ring was substituted by a chlorine atom. This was
supported by the presence of the singlet signal, which was assigned to H-2 according to the HMBC
correlations (Figure 4) of this proton to C-4 ( 102.9) and C-8a ( 102.2). Thus, it can be deduced
that the halogenation occurred at C-4 position, which is ortho to the hydroxyl group (Figure 4).
This was further supported by the HMBC correlations of H-5 ( 8.17) to C-4. Thus, 3a was
identified as 3-hydroxy-4-chloroquinoline.
The 1H and DEPTQ-135 NMR Table 2. 13C (125 MHz) NMR data for 3a, 5a, 6a and 7a (CD3OD,
of 5a also showed five CH signals, δ in ppm)
confirming that one proton of the
Position
3a
5a
6a
7a
substrate 5 was chlorinated. The
2
142.5 (CH)
149.9 (CH)
147.9 (CH) 150.2 (CH)
signal of H-2 can be easily located
in the low field at δ 8.83. Two spin
3
148.2 (C)
120.6 (CH)
122.1 (CH) 119.2 (CH)
systems were observed in the 1H4
102.9 (C)
131.7 (CH)
130.4 (CH) 137.3 (CH)
1
H COSY spectrum (Figure 4). The
4a
107.3 (C)
126.5 (C)
126.9 (C)
124.1 (C)
CH-CH-CH system belongs to the
pyridine ring, which includes H-2
5
122.5 (CH)
156.4 (C)
112.0 (C)
127.3 (CH)
( 8.83, d), H-3 ( 7.56, dd) and H6
127.9 (CH)
94.8 (C)
151.2 (C)
118.8 (CH)
4 ( 8.72, d). The CH-CH system
7
126.9 (CH)
119.8 (CH)
121.3 (CH) 155.3 (C)
consists of two protons from the
benzene ring, including the proton
8
128.2 (CH)
130.7 (CH)
129.6 (CH) 113.8 (C)
signals at  7.55 (d) and  7.68 (d).
8a
102.2 (C)
143.8 (C)
144.0 (C)
145.2 (C)
Thus, we concluded that that one of
the protons of the benzene ring was
substituted by a chlorine atom. The large coupling constant of 9.0 Hz indicated that the two CH
groups are ortho to each other. Accordingly, the possibility of C-7 halogenation can be ruled out.
Based on the HMBC correlations of both proton signals at  7.55 and 7.68 to C-8a at δ 143.8
(Figure 4), the chlorination site was determined to be at C-6. Thus, this product was identified as
5-hydroxy-6-chloroquinoline.
The 1H and DEPTQ-135 NMR spectra of 6a are similar to those of 5a. The signal of H-2 was
located in the low field at  8.80. With this signal, the spin system of H-2/H-3/H-4 was identified
by the 1H-1H COSY correlations (Figure 4). The other spin system consists of two doublet signals
from the benzene ring that belongs to H-7 and H-8, as suggested by the large coupling constant of

9.0 Hz. Accordingly, it can be deduced that C-5 of 6 was chlorinated. This was confirmed by the
HMBC correlations of H-4 ( 8.49, d) and H-7 ( 7.58, d) to C-5 at  112.0. Therefore, 6a was
characterized as 5-chloro-6-hydroxyquinoline.
The 1H NMR spectrum of 7a showed five proton signals. The presence of a CH-CH-CH spin
system in the 1H-1H COSY spectrum (Figure 4) indicated that none of the protons on the pyridine
ring was chlorinated. The 1H-1H COSY correlations of H-5 to H-6, which are doublet signals at δ
7.79 and 7.34 with a coupling constant of 8.9 Hz, respectively, indicated that Rdc2 introduced a
chlorine atom to C-8. The structure was thus characterized as 7-hydroxy-8-chloroquinoline, which
was supported by the HMBC correlations shown in Figure 4. 7a is a new compound.
Structural identification of the products 3a, 5a, 6a and 7a suggested that among the seven tested
hydroxyquinolines, four were taken by Rdc2 as substrates to form the corresponding
monochlorinated products. The chlorination reaction is highly specific as the position where the
chlorine atom was introduced is ortho to the hydroxyl group of the four substrates. This is
consistent with the results for isoquinolines in our previous studies. A number of pharmaceutically
important molecules contain a hydroxylated or chlorinated quinoline moiety, such as quinine,
quinidine, chloroquine and montelukast shown in Figure 1. Thus, the hydroxyl group and chlorine
atom attached to quinoline represent important functional groups. In this work, we generated four
quinoline derivatives that contain both functional groups at different positions.
In summary, the expression and purification Rdc2 in E. coli was improved in this work. In vitro
reactions of Rdc2 with seven hydroxyquinolines revealed that this halogenase can halogenate four
of these substrates. The corresponding products were then prepared through fermentation of the
Rdc2-expressing E. coli strain with supplemented substrates. The four products were isolated and
structurally characterized based on the UV, MS and NMR spectra. This work represents the first
enzymatic preparation of chlorohydroxyquinolines. The results further expand the reservoir of the
acceptable substrates of Rdc2, which makes it a useful biological halogenating agent in the
preparation of structurally diverse halogenated molecules.
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